Goldman Sachs Group Inc. Sells 16,800 Shares of Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX)

Goldman Sachs Group Inc. trimmed its stake in Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX) by 1.3% during the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 1,250,948 shares of the company’s stock after selling 16,800 shares during the period. Goldman Sachs Group Inc. owned about 1.47% of Syndax Pharmaceuticals worth $27,033,000 as of its most recent SEC filing.

Other large investors have also recently bought and sold shares of the company. CWM LLC grew its position in Syndax Pharmaceuticals by 415.3% in the fourth quarter. CWM LLC now owns 1,685 shares of the company’s stock valued at $36,000 after acquiring an additional 1,358 shares during the period. MeadowBrook Investment Advisors LLC acquired a new position in Syndax Pharmaceuticals in the fourth quarter worth $37,000. Quadrant Capital Group LLC boosted its stake in Syndax Pharmaceuticals by 158.3% in the fourth quarter. Quadrant Capital Group LLC now owns 2,441 shares of the company’s stock worth $53,000 after purchasing an additional 1,496 shares in the last quarter. Signaturefd LLC boosted its stake in Syndax Pharmaceuticals by 2,874.6% in the fourth quarter. Signaturefd LLC now owns 3,748 shares of the company’s stock worth $81,000 after purchasing an additional 3,622 shares in the last quarter. Finally, Annandale Capital LLC acquired a new position in Syndax Pharmaceuticals in the third quarter worth $67,000.

Syndax Pharmaceuticals Trading Up 4.0 %

NASDAQ:SNDX opened at $20.05 on Monday. Syndax Pharmaceuticals, Inc. has a 1-year low of $11.22 and a 1-year high of $25.34. The business’s 50-day moving average price is $20.59 and its two-hundred day moving average price is $21.44. The firm has a market capitalization of $1.70 billion, a price-to-earnings ratio of -6.23 and a beta of 1.01.

Syndax Pharmaceuticals (NASDAQ:SNDX) last announced its quarterly earnings results on Wednesday, May 8th. The company reported ($0.85) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.96) by $0.11. During the same period in the prior year, the company earned ($0.59) earnings per share. Sell-side analysts predict that Syndax Pharmaceuticals, Inc. will post -3.56 earnings per share for the current year.

Analyst Ratings Changes

A number of equities analysts have commented on SNDX shares. HC Wainwright reissued a “buy” rating and issued a $41.00 price objective on shares of Syndax Pharmaceuticals in a research note on Monday, June 17th. Scotiabank lowered Syndax Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a research note on Friday, June 14th. JPMorgan Chase & Co. reaffirmed an “overweight” rating and set a $34.00 price target on shares of Syndax Pharmaceuticals in a research note on Tuesday, May 21st. Stifel Nicolaus upped their price target on Syndax Pharmaceuticals from $39.00 to $40.00 and gave the company a “buy” rating in a research note on Thursday, May 9th. Finally, Citigroup cut their price target on Syndax Pharmaceuticals from $32.00 to $30.00 and set a “buy” rating on the stock in a research note on Thursday, May 9th. One research analyst has rated the stock with a sell rating, one has assigned a hold rating and ten have given a buy rating to the stock. According to MarketBeat.com, the company has a consensus rating of “Moderate Buy” and an average price target of $34.42.

Insiders Place Their Bets

In other Syndax Pharmaceuticals news, CFO Keith A. Goldan purchased 1,250 shares of the stock in a transaction on Friday, June 14th. The stock was bought at an average cost of $20.03 per share, for a total transaction of $25,037.50. Following the completion of the acquisition, the chief financial officer now directly owns 52,623 shares of the company’s stock, valued at $1,054,038.69. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Corporate insiders own 4.10% of the company’s stock.

About Syndax Pharmaceuticals

Syndax Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, develops therapies for the treatment of cancer. Its lead product candidates are revumenib, a potent, selective, small molecule inhibitor of the menin-MLL binding interaction for the treatment of KMT2A rearranged, acute leukemias, and solid tumor; and SNDX-6352 or axatilimab, a monoclonal antibody that blocks the colony stimulating factor 1, or CSF-1 receptor for the treatment of patients with chronic graft versus host disease (cGVHD) and idiopathic pulmonary fibrosis (IPF).